NewAmsterdam Pharma (NASDAQ:NAMS) Expected to Post FY2027 Earnings of ($0.16) Per Share
NewAmsterdam Pharma (NASDAQ:NAMS) Expected to Post FY2027 Earnings of ($0.16) Per Share
NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Equities research analysts at William Blair issued their FY2027 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a report issued on Monday, January 23rd. William Blair analyst M. Phipps forecasts that the company will earn ($0.16) per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is $0.27 per share.
NewAmsterdam Pharma(纳斯达克股票代码:NAMS — 获取评级)——威廉·布莱尔的股票研究分析师在1月23日星期一发布的一份报告中发布了NewAmsterdam Pharma股票的 FY2027 每股收益(EPS)估计。威廉·布莱尔分析师菲普斯预测,该公司今年的每股盈利(0.16美元)。威廉·布莱尔对该股的评级为 “跑赢大盘”。NewAmsterdam Pharma目前的全年收益的共识估计为每股0.27美元。
NAMS has been the subject of a number of other research reports. SVB Leerink began coverage on NewAmsterdam Pharma in a report on Tuesday, December 20th. They issued an "outperform" rating and a $19.00 price target for the company. Jefferies Financial Group initiated coverage on NewAmsterdam Pharma in a report on Monday, December 19th. They issued a "buy" rating and a $24.00 price target for the company. Finally, Credit Suisse Group initiated coverage on NewAmsterdam Pharma in a research report on Friday, January 6th. They issued an "outperform" rating and a $21.00 target price on the stock.
NAMS一直是许多其他研究报告的主题。SVB Leerink在12月20日星期二的一份报告中开始报道新阿姆斯特丹制药。他们为该公司发布了 “跑赢大盘” 评级和19.00美元的目标股价。杰富瑞金融集团在12月19日星期一的一份报告中开始报道NewAmsterdam Pharma。他们为该公司发布了 “买入” 评级和24.00美元的目标价。最后,瑞士信贷集团在1月6日星期五的一份研究报告中开始报道NewAmsterdam Pharma。他们对该股发布了 “跑赢大盘” 评级和21.00美元的目标价格。
NewAmsterdam Pharma Price Performance
新阿姆斯特丹制药价格表现
NewAmsterdam Pharma Company Profile
新阿姆斯特丹制药公司简介
(Get Rating)
(获取评分)
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events.
NewAmsterdam Pharma Company N.V. 是一家临床阶段的生物制药公司,为低密度脂蛋白胆固醇(LDL-C)残留升高的心血管疾病高风险患者开发口服非他汀类药物。该公司的主要候选产品是obicetrapib,这是一种口服低剂量胆固醇酯转移蛋白抑制剂,作为单一疗法和与依折替米贝联合疗法,正在进行各种临床试验,用于降低低密度脂蛋白C和预防重大心血管不良事件。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on NewAmsterdam Pharma (NAMS)
- Mergers and Acquisitions in 2023 Off To A Strong Start
- What Does Apple's Move to India Mean for Investors?
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- 免费获取 StockNews.com 关于 NewAmsterdam Pharma (NAMS) 的研究报告
- 2023年的并购有了一个良好的开端
- 苹果迁往印度对投资者意味着什么?
- AMD 仍然是目前最好的半导体股票之一
- 两位股息之王:强生还是雅培实验室?
- 网络安全股票触底了吗?
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收《新阿姆斯特丹制药日报》的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收NewAmsterdam Pharma及相关公司的最新新闻和分析师评级的简明每日摘要。